CoChat
Sign Up
Cited by 53Down syndrome and intellectual disability researchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; its reference list is not available.

Therapeutic approaches in the improvement of cognitive performance in Down syndrome

de la Torre, Rafael, Dierssen, Mara·2012·Progress in Brain Research
DOI 10.1016/b978-0-444-54299-1.00001-7
Open this paper in CoChat — free account

Abstract

Clinical trials with drugs aimed at treatment of Alzheimer disease to decelerate cognitive decline and translated mimetically to demented and young nondemented Down syndrome patients have been unable to demonstrate improvements in cognitive performance and functioning. Unfortunately, results from clinical trials do not support the use of NMDA antagonists like memantine and we should await at the development of safer GABA(A) antagonists to conclude about the efficacy of approaching Down syndrome therapeutics by modulating neurotransmission systems altered in this pathology. The use of folinic acid or antioxidants in DS patients is not supported by scientific evidence and do not provide improvement in cognitive performance to patients. Alternatively to the modulation of neurotransmission systems, future therapeutic approaches should focus at normalizing the expression levels or function of candidate molecules. Epigallocatechin gallate, a green tea polyphenol, that modulates DYRK1A functioning has already shown preliminarily that this approach may prove useful in therapeutics.

Overview

Integrity signals

Registry

Crossref · 10.1016/b978-0-444-54299-1.00001-7

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 78 · Cited by 53

Research works printed but not linked: 67

  1. Amano, 2004, Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome, Human Molecular Genetics, 13, 1333, 10.1093/hmg/ddh154 · DOI
  2. Annerén, 1999, Growth hormone treatment in young children with Down's syndrome: Effects on growth and psychomotor development, Archives of Disease in Childhood, 80, 334, 10.1136/adc.80.4.334 · DOI
  3. Belichenko, 2007, Synaptic and cognitive abnormalities in mouse models of Down syndrome: Exploring genotype–phenotype relationships, The Journal of Comparative Neurology, 504, 329, 10.1002/cne.21433 · DOI
  4. Benavides-Piccione, 2004, On dendrites in Down syndrome and DS murine models: A spiny way to learn, Progress in Neurobiology, 74, 111, 10.1016/j.pneurobio.2004.08.001 · DOI
  5. Bernert, 2001, Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome, Journal of Neural Transmission Supplementum, 61, 237
  6. Branchi, 2004, Transgenic mouse in vivo library of human Down syndrome critical region 1: Association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration, Journal of Neuropathology and Experimental Neurology, 63, 429, 10.1093/jnen/63.5.429 · DOI
  7. De Falco, 1994, Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome, Clinica Terapeutica, 144, 123
  8. Delabar, 1993, Molecular mapping of twenty-four features of Down syndrome on chromosome 21, European Journal of Human Genetics, 1, 114, 10.1159/000472398 · DOI
  9. Donmez, 2010, SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10, Cell, 142, 320, 10.1016/j.cell.2010.06.020 · DOI
  10. Edgin, 2010, Development and validation of the Arizona Cognitive Test Battery for Down syndrome, Journal of Neurodevelopmental Disorders, 2, 149, 10.1007/s11689-010-9054-3 · DOI
  11. Ellis, 2008, Supplementation with antioxidants and folinic acid for children with Down's syndrome: Randomised controlled trial, British Medical Journal, 336, 594, 10.1136/bmj.39465.544028.AE · DOI
  12. Englund, 2007, Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome, Dementia and Geriatric Cognitive Disorders, 24, 369, 10.1159/000109215 · DOI
  13. Fernandez, 2007, Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome, Nature Neuroscience, 10, 411, 10.1038/nn1860 · DOI
  14. Fernandez, 2010, EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP, FEBS Letters, 584, 4259, 10.1016/j.febslet.2010.09.022 · DOI
  15. Ferrer, 2005, Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models, Neurobiology of Disease, 20, 392, 10.1016/j.nbd.2005.03.020 · DOI
  16. Ferrer, 1990, Down's syndrome and Alzheimer's disease: Dendritic spine counts in the hippocampus, Acta Neuropathologica, 79, 680, 10.1007/BF00294247 · DOI · Paper page
  17. Fodale, 2006, The cholinergic system in Down's syndrome, Journal of Intellectual Disabilities, 10, 261, 10.1177/1744629506067615 · DOI
  18. Gasperi, 2010, Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases, Journal of Endocrinological Investigation, 33, 587, 10.1007/BF03346653 · DOI
  19. Golden, 1994, Development of the superior temporal neocortex is anomalous in trisomy 21, Journal of Neuropathology and Experimental Neurology, 53, 513, 10.1097/00005072-199409000-00011 · DOI · Paper page
  20. Guedj, 2009, Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A, PLoS One, 4, e4606, 10.1371/journal.pone.0004606 · DOI
  21. Hampel, 2010, Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives, Nature Reviews. Drug Discovery, 9, 560, 10.1038/nrd3115 · DOI
  22. Hanney, 2012, Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial, Lancet, 379, 528, 10.1016/S0140-6736(11)61676-0 · DOI
  23. Haydar, 2012, Trisomy 21 and early brain development, Trends Neuroscience, 35, 81, 10.1016/j.tins.2011.11.001 · DOI · Paper page
  24. Heller, 2010, Safety and efficacy of rivastigmine in adolescents with Down syndrome: Long-term follow-up, Journal of Child and Adolescent Psychopharmacology, 20, 517, 10.1089/cap.2009.0099 · DOI
  25. Heller, 2004, Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial, American Journal of Medical Genetics. Part A, 130A, 325, 10.1002/ajmg.a.30184 · DOI
  26. Heller, 2003, Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial, American Journal of Medical Genetics. Part A, 116A, 111, 10.1002/ajmg.a.10074 · DOI
  27. Johnson, 2003, Effects of donepezil on cognitive functioning in Down syndrome, American Journal of Mental Retardation, 108, 367, 10.1352/0895-8017(2003)108<367:EODOCF>2.0.CO;2 · DOI · Paper page
  28. Jones, 2009, Amyloid beta concentrations in older people with Down syndrome and dementia, Neuroscience Letters, 451, 162, 10.1016/j.neulet.2008.12.030 · DOI
  29. Khoshnood, 2011, Paper 2: EUROCAT public health indicators for congenital anomalies in Europe, Birth Defects Research. Part A Clinical and Molecular Teratology, 91, S16, 10.1002/bdra.20776 · DOI
  30. Kishnani, 2010, Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17, American Journal of Medical Genetics. Part A, 152A, 3028, 10.1002/ajmg.a.33730 · DOI
  31. Kishnani, 2009, The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome, American Journal of Medical Genetics. Part A, 149A, 1641, 10.1002/ajmg.a.32953 · DOI
  32. Kishnani, 1999, Cholinergic therapy for Down's syndrome, Lancet, 353, 1064, 10.1016/S0140-6736(98)05285-4 · DOI
  33. Kondoh, 2011, Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: A 24-week randomized, double-blind, placebo-controlled trial, International Journal of Psychiatry in Medicine, 41, 71, 10.2190/PM.41.1.g · DOI
  34. Lepagnol-Bestel, 2009, DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome, Human Molecular Genetics, 18, 1405, 10.1093/hmg/ddp047 · DOI
  35. Lichtenthaler, 2011, Alpha-secretase in Alzheimer's disease: Molecular identity, regulation and therapeutic potential, Journal of Neurochemistry, 116, 10, 10.1111/j.1471-4159.2010.07081.x · DOI
  36. Lobaugh, 2001, Piracetam therapy does not enhance cognitive functioning in children with down syndrome, Archives of Pediatrics & Adolescent Medicine, 155, 442, 10.1001/archpedi.155.4.442 · DOI
  37. Lott, 2010, Cognitive deficits and associated neurological complications in individuals with Down's syndrome, Lancet Neurology, 9, 623, 10.1016/S1474-4422(10)70112-5 · DOI · Paper page
  38. Lott, 2002, Down syndrome and Alzheimer disease: Response to donepezil, Archives of Neurology, 59, 1133, 10.1001/archneur.59.7.1133 · DOI
  39. Martinez de Lagran, 2004, Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction, Neurobiology of Disease, 15, 132, 10.1016/j.nbd.2003.10.002 · DOI
  40. Mohan, 2009, Memantine for dementia in people with Down syndrome, Cochrane Database of Systematic Reviews, 1
  41. Myrelid, 2010, Late effects of early growth hormone treatment in Down syndrome, Acta Paediatrica, 99, 763, 10.1111/j.1651-2227.2009.01679.x · DOI
  42. Obregon, 2006, ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein, Journal of Biological Chemistry, 281, 16419, 10.1074/jbc.M600617200 · DOI
  43. Olson, 2007, Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice, Human Molecular Genetics, 16, 774, 10.1093/hmg/ddm022 · DOI
  44. Ortiz-Abalia, 2008, Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome, American Journal of Human Genetics, 83, 479, 10.1016/j.ajhg.2008.09.010 · DOI
  45. Palacios, 2011, Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease, CNS & Neurological Disorders Drug Targets, 10, 149, 10.2174/187152711794480474 · DOI
  46. Petersen, 2009, Use of Alzheimer disease biomarkers: Potentially yes for clinical trials but not yet for clinical practice, Journal of the American Medical Association, 302, 436, 10.1001/jama.2009.1073 · DOI
  47. Prasher, 2004, Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: Implications for the intellectual disability population, International Journal of Geriatric Psychiatry, 19, 509, 10.1002/gps.1077 · DOI
  48. Prasher, 2005, Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome, International Journal of Geriatric Psychiatry, 20, 496, 10.1002/gps.1306 · DOI
  49. Prasher, 2003, Down Syndrome Research Group. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study, International Journal of Geriatric Psychiatry, 18, 549, 10.1002/gps.859 · DOI
  50. Prasher, 2002, Down syndrome Ageing Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease–pilot study, International Journal of Geriatric Psychiatry, 17, 270, 10.1002/gps.587 · DOI
  51. Prasher, 2010, Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome, International Journal of Geriatric Psychiatry, 25, 202, 10.1002/gps.2321 · DOI
  52. Prinzen, 2009, Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice, BMC Genomics, 10, 66, 10.1186/1471-2164-10-66 · DOI
  53. Pueschel, 2006, The effect of acetyl-L-carnitine administration on persons with Down syndrome, Research in Developmental Disabilities, 27, 599, 10.1016/j.ridd.2004.07.009 · DOI
  54. Rissman, 2011, Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease, Journal of Neurochemistry, 117, 613
  55. Ronan, 2007, Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region, Journal of Medical Genetics, 44, 448, 10.1136/jmg.2006.047373 · DOI
  56. Rueda, 2010, Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome, Journal of Alzheimer's Disease, 21, 277, 10.3233/JAD-2010-100240 · DOI
  57. Ryu, 2010, Dyrk1A-mediated phosphorylation of Presenilin 1: A functional link between Down syndrome and Alzheimer's disease, Journal of Neurochemistry, 115, 574, 10.1111/j.1471-4159.2010.06769.x · DOI
  58. Salman, 2002, Systematic review of the effect of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome, European Journal of Paediatric Neurology, 6, 213, 10.1053/ejpn.2002.0596 · DOI
  59. Schmidt-Sidor, 1990, Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months, Clinical Neuropathology, 9, 181
  60. Schupf, 2010, Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome, Neurology, 75, 1639, 10.1212/WNL.0b013e3181fb448b · DOI
  61. Seidl, 2000, Effects of transdermal nicotine on cognitive performance in Down's syndrome, Lancet, 356, 1409, 10.1016/S0140-6736(00)02848-8 · DOI
  62. Shichiri, 2011, α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome, Free Radical Biology & Medicine, 50, 1801, 10.1016/j.freeradbiomed.2011.03.023 · DOI
  63. Spiridigliozzi, 2007, Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series, American Journal of Medical Genetics. Part A, 143A, 1408, 10.1002/ajmg.a.31790 · DOI
  64. Tian, 2010, Dual role of alpha-secretase cleavage in the regulation of gamma-secretase activity for amyloid production, Journal of Biological Chemistry, 285, 32549, 10.1074/jbc.M110.128439 · DOI · Paper page
  65. Wegiel, 2011, The role of DYRK1A in neurodegenerative diseases, FEBS Journal, 278, 236, 10.1111/j.1742-4658.2010.07955.x · DOI
  66. Wegiel, 2011, Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome, Journal of Neuropathology and Experimental Neurology, 70, 36, 10.1097/NEN.0b013e318202bfa1 · DOI
  67. Yamamoto, 2011, Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6, American Journal of Medical Genetics. Part A, 155A, 113, 10.1002/ajmg.a.33735 · DOI

Metadata

Authors
de la Torre, R., & Dierssen, M.
Affiliations
Municipal Institute for Medical Research (ES)
Corresponding author
de la Torre, Rafael
ORCID
Venue
Progress in Brain Research
Publisher
Elsevier
Published
2012
Volume
197
Pages
1-14
ISSN
0079-6123 (ISSN-L)
DOI
10.1016/b978-0-444-54299-1.00001-7
OpenAlex
W1497218644
Cited by
53
References
78
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 1 · 2019: 7 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 9 · 2013: 1 · 2012: 1
FWCI
12.64
Type
book chapter
Language
en
Open access
closed
Locations
  • Progress in brain research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Down syndrome, cognitive performance, Alzheimer's disease, NMDA receptor antagonists, memantine, leucovorin, antioxidants, epigallocatechin gallate, DYRK1A, neurotransmitter modulation, cognitive decline
MeSH terms
Clinical Trials as Topic, Cognition Disorders, Down Syndrome, Humans, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review